Makers of crucial lab equipment and materials for the healthcare industry play a vital, though often overlooked, role for some higher-risk companies.
Test enables identification of patients whose tumors express PD-L1 for potential treatment with KEYTRUDA® (pembrolizumab) 1, 2
Q4 Earnings Outperformers: Agilent (NYSE:A) And The Rest Of The Research Tools & Consumables Stocks
Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice
/Waters%20Corp_%20phone%20logo%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
Waters Corporation stock has underperformed the Dow over the past year, but analysts remain moderately bullish about its prospects.
2 Large-Cap Stocks to Research Further and 1 We Brush Off
Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) solution integrating the company’s...
/Agilent%20Technologies%20Inc_%20phone%20and%20logo-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Although Agilent Technologies has underperformed the S&P 500 recently, analysts remain highly optimistic about the stock’s prospects.
/IQVIA%20Holdings%20Inc%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
IQVIA Holdings has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 ...